ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.16
0.00%
US Tech 100
18,271.20
0.53%
S&P 500
5,291.34
0.00%
US Dollar vs CAD
1.36825
0.04%
Bitcoin
71,085.77
0.65%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) News

ARVN Arvinas Inc

29.12
0.00 (0.00%)
Pre Market
Last Updated: 07:31:52
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Arvinas Inc ARVN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 29.12 07:31:52
Open Price Low Price High Price Close Price Previous Close
29.12
more quote information »

Recent News

Date Time Source Heading
6/03/202415:30GLOBEArvinas to Participate in Upcoming Investor Conferences
5/31/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
5/30/202415:52EDGAR2Form 8-K - Current report
5/23/202420:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
5/23/202416:00GLOBEArvinas Announces Upcoming Presentations at the 2024..
5/16/202405:05EDGAR2Form 8-K - Current report
5/16/202405:00GLOBEArvinas and Pfizer Announce Updated Clinical Data from Phase..
5/09/202415:42GLOBEArvinas Announces Upcoming Vepdegestrant Poster..
5/07/202415:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/07/202406:02EDGAR2Form 8-K - Current report
5/07/202406:00GLOBEArvinas Reports First Quarter 2024 Financial Results and..
5/02/202406:00GLOBEArvinas to Present at Upcoming Investor Conferences
4/24/202415:30GLOBEArvinas Appoints Randy Teel, Ph.D., as Chief Business..
4/11/202406:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
3/18/202415:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
3/04/202406:00GLOBEArvinas to Participate in Upcoming Investor Conferences
2/27/202417:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202417:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202417:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202417:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202415:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/27/202406:02EDGAR2Form 8-K - Current report
2/27/202406:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
2/20/202415:06EDGAR2Form 8-K - Current report
2/20/202415:05GLOBEArvinas Announces Chief Financial Officer Transition
2/20/202406:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
2/14/202407:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
2/13/202419:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/06/202405:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
2/01/202415:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
1/16/202416:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
1/16/202415:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
1/08/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/08/202406:45EDGAR2Form 8-K - Current report
12/08/202308:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
12/06/202306:01EDGAR2Form 8-K - Current report
12/05/202321:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
12/05/202312:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
11/28/202316:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
11/27/202306:11EDGAR2Form 8-K - Current report
11/27/202306:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
11/07/202316:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
11/07/202315:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/202306:03EDGAR2Form 8-K - Current report
11/07/202306:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
11/02/202306:00GLOBEArvinas to Participate in Upcoming Investor Conferences
10/23/202307:30EDGAR2Form 8-K - Current report
10/22/202306:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
10/18/202306:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
10/15/202317:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..

Your Recent History

NASDAQ
ARVN
Arvinas
LSE
TALK
Talktalk Telecom
BMF
OC1X24
OC1X24 - Novembro 2024
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved